BioStock: Chordate Medical starts post-market study in four markets

Chordate Medical is currently underway with its clinical post-market study with Ozilia. The study is an important part of the regulatory requirements for CE marking and can also provide valuable data on optimal treatment frequency. BioStock reached out to the company’s Medical Director, Jan Hermansson, to find out more. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/chordate-medical-starts-post-market-study-in-four-markets/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se